Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Utility of 18FDG-PET/CT for risk prediction in patients with R/R myeloma undergoing CAR-T therapy

Luis-Esteban Tamariz-Amador, MD, University Clinic of Navarra, Pamplona, Spain, briefly discusses a study exploring the value of using 18FDG-PET/CT when treating patients with relapsed/refractory (R/R) multiple myeloma with CAR-T cells. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.